MedTrace Logo

Long-Term Safety and Effectiveness of MDMA-Assisted Therapy for PTSD

NCT05066282 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 186

Last updated 2024-10-30

No results posted yet for this study

Summary

The goal of this long-term follow-up study is to measure how long effects of MDMA-assisted therapy last in participants with PTSD who were treated in a prior Phase 3 clinical trial of MDMA-assisted therapy.

The main question it aims to answer is: Does MDMA-assisted therapy result in lasting reductions in PTSD symptoms?

Participants who have received at least one dose of MDMA-assisted therapy will take a PTSD assessment at least six months after their last MDMA-assisted therapy session in the main study.

Conditions

Sponsors & Collaborators

Principal Investigators

  • Jennifer Mitchell, MD · University of California, San Francisco

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-01
Primary Completion
2024-05-16
Completion
2024-05-21

Countries

  • United States
  • Canada
  • Israel

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05066282 on ClinicalTrials.gov